Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status

Jennifer Rodriguez-Rivera, Larry Denner, Kelly Dineley

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Converging lines of evidence associate gluco-regulatory abnormalities and peroxisome-proliferator-activated receptor (PPAR) gamma function with increased risk for Alzheimer's disease (AD). In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. We assessed cognition and peripheral gluco-regulatory status of Tg2576 mice following 1 month treatment with RTZ initiated prior to, coincident with, or after, the onset of peripheral gluco-regulatory abnormalities (4, 8, and 12 months of age, respectively). Whereas 5 months old (MO) and 13 MO Tg2576 did not gain cognitive improvement after 1 month treatment with RTZ, 9 MO Tg2576 mice exhibited reversal of associative learning and memory deficits. Peripheral gluco-regulatory abnormalities were improved in 9 and 13 MO Tg2576 with RTZ treatment; RTZ treatment had no effect on the normal glucose status of 5 MO Tg2576 mice. These findings suggest that RTZ-mediated cognitive improvement does not correlate with peripheral gluco-regulatory abnormalities per se, but reflects the age-dependent mechanistic differences that underlie cognitive decline in this mouse model.

Original languageEnglish (US)
Pages (from-to)255-261
Number of pages7
JournalBehavioural Brain Research
Volume216
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

rosiglitazone
PPAR gamma
Alzheimer Disease
Reversal Learning
Memory Disorders
Cognition

Keywords

  • Alzheimer's disease
  • Fear conditioning
  • Glucose tolerance test
  • Hippocampus-dependent learning and memory
  • Insulin
  • Mouse model
  • PPARγ

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. / Rodriguez-Rivera, Jennifer; Denner, Larry; Dineley, Kelly.

In: Behavioural Brain Research, Vol. 216, No. 1, 01.01.2011, p. 255-261.

Research output: Contribution to journalArticle

@article{398ca025fc7647e591b958553adb126a,
title = "Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status",
abstract = "Converging lines of evidence associate gluco-regulatory abnormalities and peroxisome-proliferator-activated receptor (PPAR) gamma function with increased risk for Alzheimer's disease (AD). In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. We assessed cognition and peripheral gluco-regulatory status of Tg2576 mice following 1 month treatment with RTZ initiated prior to, coincident with, or after, the onset of peripheral gluco-regulatory abnormalities (4, 8, and 12 months of age, respectively). Whereas 5 months old (MO) and 13 MO Tg2576 did not gain cognitive improvement after 1 month treatment with RTZ, 9 MO Tg2576 mice exhibited reversal of associative learning and memory deficits. Peripheral gluco-regulatory abnormalities were improved in 9 and 13 MO Tg2576 with RTZ treatment; RTZ treatment had no effect on the normal glucose status of 5 MO Tg2576 mice. These findings suggest that RTZ-mediated cognitive improvement does not correlate with peripheral gluco-regulatory abnormalities per se, but reflects the age-dependent mechanistic differences that underlie cognitive decline in this mouse model.",
keywords = "Alzheimer's disease, Fear conditioning, Glucose tolerance test, Hippocampus-dependent learning and memory, Insulin, Mouse model, PPARγ",
author = "Jennifer Rodriguez-Rivera and Larry Denner and Kelly Dineley",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.bbr.2010.08.002",
language = "English (US)",
volume = "216",
pages = "255--261",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status

AU - Rodriguez-Rivera, Jennifer

AU - Denner, Larry

AU - Dineley, Kelly

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Converging lines of evidence associate gluco-regulatory abnormalities and peroxisome-proliferator-activated receptor (PPAR) gamma function with increased risk for Alzheimer's disease (AD). In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. We assessed cognition and peripheral gluco-regulatory status of Tg2576 mice following 1 month treatment with RTZ initiated prior to, coincident with, or after, the onset of peripheral gluco-regulatory abnormalities (4, 8, and 12 months of age, respectively). Whereas 5 months old (MO) and 13 MO Tg2576 did not gain cognitive improvement after 1 month treatment with RTZ, 9 MO Tg2576 mice exhibited reversal of associative learning and memory deficits. Peripheral gluco-regulatory abnormalities were improved in 9 and 13 MO Tg2576 with RTZ treatment; RTZ treatment had no effect on the normal glucose status of 5 MO Tg2576 mice. These findings suggest that RTZ-mediated cognitive improvement does not correlate with peripheral gluco-regulatory abnormalities per se, but reflects the age-dependent mechanistic differences that underlie cognitive decline in this mouse model.

AB - Converging lines of evidence associate gluco-regulatory abnormalities and peroxisome-proliferator-activated receptor (PPAR) gamma function with increased risk for Alzheimer's disease (AD). In this study, we used the Tg2576 AD mouse model to test the hypothesis that cognitive improvement following 1 month of PPAR gamma agonism with rosiglitazone (RTZ) correlates with peripheral gluco-regulatory status. We assessed cognition and peripheral gluco-regulatory status of Tg2576 mice following 1 month treatment with RTZ initiated prior to, coincident with, or after, the onset of peripheral gluco-regulatory abnormalities (4, 8, and 12 months of age, respectively). Whereas 5 months old (MO) and 13 MO Tg2576 did not gain cognitive improvement after 1 month treatment with RTZ, 9 MO Tg2576 mice exhibited reversal of associative learning and memory deficits. Peripheral gluco-regulatory abnormalities were improved in 9 and 13 MO Tg2576 with RTZ treatment; RTZ treatment had no effect on the normal glucose status of 5 MO Tg2576 mice. These findings suggest that RTZ-mediated cognitive improvement does not correlate with peripheral gluco-regulatory abnormalities per se, but reflects the age-dependent mechanistic differences that underlie cognitive decline in this mouse model.

KW - Alzheimer's disease

KW - Fear conditioning

KW - Glucose tolerance test

KW - Hippocampus-dependent learning and memory

KW - Insulin

KW - Mouse model

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=78149407291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149407291&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2010.08.002

DO - 10.1016/j.bbr.2010.08.002

M3 - Article

VL - 216

SP - 255

EP - 261

JO - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

IS - 1

ER -